Michael D. Prados, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Michael D. Prados, MD

Professor, Department of Neurological Surgery, and Director of Translational Research in Neuro-Oncology, UCSF; Leader, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
Charles B. Wilson, MD, Endowed Chair in Neurological Surgery, UCSF

Phone: (415) 353-2966 (appts)
Box 0372, UCSF
San Francisco, CA 94143-0372

View on UCSF Profiles

Cancer Center Membership

Program Member » Neurologic Oncology» Pediatric Malignancies

Research Summary

I have been involved in clinical and translational research in early-phase clinical trials for both children and adults with CNS malignancies since 1985. I have served as Project Leader (the North American Brain Tumor Consortium) or co-Project Leader (the Adult Brain Tumor Consortium) for 20 years. I had been the institutional Principal Investigator of the UCSF Member Institution for the Pediatric Brain Tumor Consortium for many years. I currently am Project Leader of the Ivy Foundation Early Phase Clinical Trials Consortium (seven member institutions) and Project Leader for the Pacific Pediatric Neuro-Oncology Consortium (eleven member institutions). I previously was the Program Leader for the Neurological Oncology Program for the HDFCCC, and previously the Director of Translational Research in Neuro-Oncology. In addition, I am the Clinical co-Leader of the UCSF Brain Tumor SPORE grant, and co-leader of the Clinical and Statistical Core, Administrative Core, and Project 3 co-leader within that grant.

Education

Mississippi State University, Starkville, 1966-1969, Biology
University of New Orleans, BS, 1969-1970, Biology
LSU School of Medicine, MD, 1970-1974, Medicine
LSU Charity Hospital, New Orleans, LA, Internship, 1974-1975, Medicine
LSU Earl K Long Hospital, Baton Rouge, LA, Residency, 1975-1977, Internal Medicine


Professional Experience

  • 1977-1978
    Instructor, Department of Internal Medicine, LSU School of Medicine, New Orleans, LA
  • 1979-1982
    Assistant Professor, Department of Medicine, LSU School of Medicine, Earl K Long Hospital, Baton Rouge, LA
  • 1980-1982
    Clinical Director, Medical Oncology, Dept. of Medicine, LSU School of Medicine, Earl K Long Hospital, Baton Rouge, LA
  • 1983-1984
    Pulmonary Fellowship (12 months), Tulane University School of Medicine, New Orleans, LA
  • 1984-1985
    Asst. Clinical Director, Dept. of Pulmonary Medicine, Touro Infirmary, New Orleans, LA
  • 1985-1987
    Clinical Instructor, Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, University of California, San Francisco, CA
  • 1988-1991
    Asst. Clinical Prof., Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, School of Medicine, University of California, San Francisco, CA
  • 1988-1989
    Acting Director, Neuro-Oncology Program, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco
  • 1989-2005
    Director, Neuro-Oncology Program, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco
  • 1991-1995
    Assoc. Clinical Professor, Chief, Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, School of Medicine, University of California, San Francisco, CA
  • 1995-present
    Professor in Residence, Dept. of Neurological Surgery, University of California, San Francisco
  • 2001-present
    Charles B. Wilson Professor of Neurological Surgery, University of California, San Francisco
  • 2005 - present
    Director of the Translational Research Program in Neuro-Oncology, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco

Selected Publications

  1. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget. 2015 Dec 4.
    View on PubMed
  2. Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. Transl Oncol. 2015 Dec; 8(6):446-55.
    View on PubMed
  3. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015 Sep 8; 6(26):21993-2005.
    View on PubMed
  4. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. J Clin Oncol. 2015 Oct 1; 33(28):3186-92.
    View on PubMed
  5. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53.
    View on PubMed
  6. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5.
    View on PubMed
  7. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015 Aug 20; 33(24):2646-54.
    View on PubMed
  8. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015 Jun 25; 372(26):2499-508.
    View on PubMed
  9. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63.
    View on PubMed
  10. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. J Neurooncol. 2015 Jan; 121(2):331-9.
    View on PubMed
  11. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47.
    View on PubMed
  12. Familial gliomas: cases in two pairs of brothers. J Neurooncol. 2015 Jan; 121(1):135-40.
    View on PubMed
  13. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8.
    View on PubMed
  14. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol. 2015 Mar; 17(3):440-7.
    View on PubMed
  15. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul; 16(7):984-90.
    View on PubMed
  16. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet. 2014 Jul; 46(7):731-5.
    View on PubMed
  17. Plexiform neurofibromas, trial design, and the definitions of "progression" and "treatment failure". Neuro Oncol. 2014 May; 16(5):617-8.
    View on PubMed
  18. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014 May; 46(5):462-6.
    View on PubMed
  19. "We will know it when we see it;" bevacizumab and glioblastoma. Neuro Oncol. 2014 Apr; 16(4):469-70.
    View on PubMed
  20. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014 Sep; 16(9):1255-62.
    View on PubMed

Go to UCSF Profiles, powered by CTSI